Latest Jazz Pharmaceuticals plc Stories
HEMEL HEMPSTEAD, England, March 23, 2015 /PRNewswire/ -- EUSA Pharma (EUSA), a newly-established profitable specialty pharmaceutical business with global reach, today announced
Company Reports Total Revenues of $1.17 Billion in 2014 Driven by Strong Sales of Xyrem, Erwinaze and Defitelio DUBLIN, Feb.
Three Oral Presentations Provide New Analyses of the Efficacy and Safety of Defibrotide in Patients with VOD, Including Post-Hoc Sub-Group Analyses in Children, Adults, and Allograft and Autograft
DUBLIN, Jan. 5, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 33(rd) Annual J.P.
Expanded U.S. Labeling Offers an Alternative Method to Administer Erwinaze to Patients with ALL DUBLIN, Dec.
Expects to complete submission in the first half of 2015 DUBLIN, Dec.
Trial Initiated in Response to a FDA Pediatric Written Request to Study Xyrem in Children and Adolescents DUBLIN, Dec.
Posters Include an Epidemiological Measure of the Effectiveness Analysis of Defibrotide from a Phase 3 Trial in Severe Hepatic VOD, as well as Updates from an International Compassionate Use Program
- Large; stout; burly.